BLK
MOLECULAR TARGETBLK proto-oncogene, Src family tyrosine kinase
BLK (BLK proto-oncogene, Src family tyrosine kinase) is targeted by 8 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting BLK
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Dasatinib | 1.10 | 2 |
| 2 | Afatinib | 0.69 | 1 |
| 3 | alsterpaullone | 0.69 | 1 |
| 4 | Axitinib | 0.69 | 1 |
| 5 | Crizotinib | 0.69 | 1 |
| 6 | Sorafenib | 0.69 | 1 |
| 7 | sp600125 | 0.69 | 1 |
| 8 | tyrphostin ag 1478 | 0.69 | 1 |
About BLK as a Drug Target
BLK (BLK proto-oncogene, Src family tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 8 compounds with documented BLK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
BLK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.